国际麻醉学与复苏杂志   2017, Issue (12): 0-0
    
微小核糖核酸在阿尔茨海默病中的研究进展
徐堂文, 刘奕君1()
1.潍坊医学院(在读研究生),目前在青岛市市立医院规陪
Roles of microRNA in the pathophysiology of Alzheimer's disease
 全文:
摘要:

背景 微小核糖核酸(microRNA, miRNA)是一类由22个核苷酸组成的非编码单链RNA。它们可直接降解mRNA及转录后阻断目标基因的翻译。通过这些过程,miRNAs调节了各种生理功能,包括阿尔茨海默病(Alzheimer's disease, AD)的发生和发展。 目的 回顾miRNA对AD患者中的β淀粉样蛋白、tau蛋白、神经性炎症和突触可塑性的影响。 内容 淀粉样斑块和神经元纤维缠结是AD的主要病理生理特点。淀粉样斑块主要组成成分是β淀粉样蛋白(β-amyloid peptide, Aβ),而神经原纤维缠结的主要形成机制是tau蛋白的过度磷酸化。在AD的某些阶段中,一些miRNA促进或减少Aβ的积累或tau蛋白的磷酸化;一些miRNA通过TNF?蛳α/NF-κB通路或IL-1/IL-6控制炎性反应来调节AD的发生与发展。miRNA的水平也参与了AD患者中突触可塑性的损害。 趋向 病理证据表明,miRNA可能在AD的发生过程中起重要作用,一些miRNA可能是AD阶段性分类的潜在生物标记。需要进一步的机制研究来阐明miRNA是否可以作为逆转或抑制AD恶化的治疗靶点。

关键词: 微小核糖核酸; 阿尔茨海默病
Abstract:

Background Alzheimer's disease(AD) is the most common neurodegenerative disorder in the elderly with dementia as featured symptom. The microRNA(miRNA) are a class of non-coding single-stranded RNA composed of 22 nucleotides. They target coding miRNA and cause degradation of the miRNA, inhibiting their translation. Through these procedures, miRNA regulate various physiological functions, including the development and progress of AD. Objective To review the effects of miRNA on the levels of β-amyloid peptide(Aβ) and tau, neuroinflammation, and synaptic plasticity in AD. Content Amyloid plaques and neurofibrillary tangles are major pathophysiological hallmarks of AD. Amyloid plaques are formed by the accumulation of Aβ, while neurofibrillary tangles are generated by the excess phosphorylation of tau protein. Some miRNA were discovered to promote or reduce the accumulation of Aβ or production/phosphorylation of tau protein in certain stages of AD. Some miRNA modulate inflammation through TNF-α/NF-κB pathway or IL-1/IL-6 pathway, regulating the development and progress of AD. The levels of miRNA are also demonstrated to involve in the impairment of synaptic plasticity in AD. Trend Pathological evidence has demonstrated that miRNA may play important role in the progress of AD, suggesting that some miRNA can be potential biomarkers for stage classifications of AD. Further mechanistic investigations are required to clarify whether miRNA can be therapeutic targets to reverse or curb the deterioration of AD.

Key words: MicroRNA; Alzheimer's disease